Nanobodies as modulators of inflammation: Potential applications for acute brain injury

Frontiers in Cellular Neuroscience

Volumn 8, Issue OCT, 2014, Pages

  Rissiek, Björn ^a   Koch Nolte, Friedrich ^a   Magnus, Tim ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Blood brain barrier; Nanobodies; Neuroinflammation; Single domain antibodies; VHH

Indexed keywords

NANOBODY;

ANTIGENIC MODULATION; ARTICLE; BLOOD BRAIN BARRIER; BRAIN INJURY; DRUG DELIVERY SYSTEM; IMMUNOMODULATION; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PH; PROTEIN EXPRESSION;

EID: 84908227670     PISSN: 16625102     EISSN: None     Source Type: Journal    
DOI: 10.3389/fncel.2014.00344     Document Type: Article

References (55)

1. Abulrob, A., Sprong, H., Van Bergen en Henegouwen, P., and Stanimirovic, D. (2005). The blood-brain barrier transmigrating single domain antibody: mechanisms of transport and antigenic epitopes in human brain endothelial cells. J. Neurochem. 95, 1201-1214. doi: 10.1111/j.1471-4159.2005.03463.x
2. Amantea, D., Nappi, G., Bernardi, G., Bagetta, G., and Corasaniti, M. T. (2009). Post-ischemic brain damage: pathophysiology and role of inflammatory mediators. FEBS J. 276, 13-26. doi: 10.1111/j.1742-4658.2008.06766.x
3. Arbabi Ghahroudi, M., Desmyter, A., Wyns, L., Hamers, R., and Muyldermans, S. (1997). Selection and identification of single domain antibody fragments from camel heavy-chain antibodies. FEBS Lett. 414, 521-526. doi: 10.1016/s0014-5793(97)01062-4
4. Arbeloa, J., Pérez-Samartín, A., Gottlieb, M., and Matute, C. (2012). P2X7 receptor blockade prevents ATP excitotoxicity in neurons and reduces brain damage after ischemia. Neurobiol. Dis. 45, 954-961. doi: 10.1016/j.nbd.2011.12.014
5. Bartlett, R., Stokes, L., and Sluyter, R. (2014). The P2X7 receptor channel: recent developments and the use of P2X7 antagonists in models of disease. Pharmacol. Rev. 66, 638-675. doi: 10.1124/pr.113.008003
6. Behar, G., Chames, P., Teulon, I., Cornillon, A., Alshoukr, F., Roquet, F., et al. (2009). Llama single-domain antibodies directed against nonconventional epitopes of tumor-associated carcinoembryonic antigen absent from nonspecific cross-reacting antigen. FEBS J. 276, 3881-3893. doi: 10.1111/j.1742-4658.2009.07101.x
7. Behar, G., Sibéril, S., Groulet, A., Chames, P., Pugnière, M., Boix, C., et al. (2008). Isolation and characterization of anti-FcgammaRIII (CD16) llama single-domain antibodies that activate natural killer cells. Protein Eng. Des. Sel. 21, 1-10. doi: 10.1093/protein/gzm064
8. Blanc, M. R., Anouassi, A., Abed, M. A., Tsikis, G., Canepa, S., Labas, V., et al. (2009). A one-step exclusion-binding procedure for the purification of functional heavy-chain and mammalian-type γ globulins from camelid sera. Biotechnol. Appl. Biochem. 54, 207-212. doi: 10.1042/ba20090208
9. Blanchetot, C., Verzijl, D., Mujić-Delić, A., Bosch, L., Rem, L., Leurs, R., et al. (2013). Neutralizing nanobodies targeting diverse chemokines effectively inhibit chemokine function. J. Biol. Chem. 288, 25173-25182. doi: 10.1074/jbc.m113.467969
10. Boado, R. J., Hui, E. K.-W., Lu, J. Z., and Pardridge, W. M. (2012). Glycemic control and chronic dosing of rhesus monkeys with a fusion protein of iduronidase and a monoclonal antibody against the human insulin receptor. Drug Metab. Dispos. 40, 2021-2025. doi: 10.1124/dmd.112.046375
11. Choe, C.-U., Lardong, K., Gelderblom, M., Ludewig, P., Leypoldt, F., Koch-Nolte, F., et al. (2011). CD38 exacerbates focal cytokine production, postischemic inflammation and brain injury after focal cerebral ischemia. PLoS One 6:e19046. doi: 10.1371/journal.pone.0019046
12. Cisneros-Mejorado, A., Pérez-Samartín, A., Gottlieb, M., and Matute, C. (2014). ATP signaling in brain: release, excitotoxicity and potential therapeutic targets. Cell. Mol. Neurobiol. doi: 10.1007/s10571-014-0092-3. [Epub ahead of print].
13. Clackson, T., Hoogenboom, H. R., Griffiths, A. D., and Winter, G. (1991). Making antibody fragments using phage display libraries. Nature 352, 624-628. doi: 10.1038/352624a0
14. Cooper, P. R., Ciambrone, G. J., Kliwinski, C. M., Maze, E., Johnson, L., Li, Q., et al. (2013). Efflux of monoclonal antibodies from rat brain by neonatal Fc receptor, FcRn. Brain Res. 1534, 13-21. doi: 10.1016/j.brainres.2013.08.035
15. Coppieters, K., Dreier, T., Silence, K., de Haard, H., Lauwereys, M., Casteels, P., et al. (2006). Formatted anti-tumor necrosis factor alpha VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen-induced arthritis. Arthritis Rheum. 54, 1856-1866. doi: 10.1002/art.21827
16. De Genst, E., Silence, K., Decanniere, K., Conrath, K., Loris, R., Kinne, J., et al. (2006). Molecular basis for the preferential cleft recognition by dromedary heavy-chain antibodies. Proc. Natl. Acad. Sci. U S A 103, 4586-4591. doi: 10.1073/pnas.0505379103
17. Dumoulin, M., Conrath, K., Van Meirhaeghe, A., Meersman, F., Heremans, K., Frenken, L. G. J., et al. (2002). Single-domain antibody fragments with high conformational stability. Protein Sci. 11, 500-515. doi: 10.1110/ps.34602
18. Farrington, G. K., Caram-Salas, N., Haqqani, A. S., Brunette, E., Eldredge, J., Pepinsky, B., et al. (2014). A novel platform for engineering blood-brain barrier-crossing bispecific biologics. FASEB J. doi: 10.1096/fj.14-253369. [Epub ahead of print].
19. Farrington, G. K., and Sisk, W. (2013). Enhancement of transport of therapeutic molecules across the blood brain barrier. Patent
20. Garcin, G., Paul, F., Staufenbiel, M., Bordat, Y., Van der Heyden, J., Wilmes, S., et al. (2014). High efficiency cell-specific targeting of cytokine activity. Nat. Commun. 5:3016. doi: 10.1038/ncomms4016
21. Hamers-Casterman, C., Atarhouch, T., Muyldermans, S., Robinson, G., Hamers, C., Songa, E. B., et al. (1993). Naturally occurring antibodies devoid of light chains. Nature 363, 446-448. doi: 10.1038/363446a0
22. Hassanzadeh-Ghassabeh, G., Devoogdt, N., De Pauw, P., Vincke, C., and Muyldermans, S. (2013). Nanobodies and their potential applications. Nanomedicine (Lond) 8, 1013-1026. doi: 10.2217/nnm.13.86
23. Huang, J., Li, Y., Tang, Y., Tang, G., Yang, G.-Y., and Wang, Y. (2013). CXCR4 antagonist AMD3100 protects blood-brain barrier integrity and reduces inflammatory response after focal ischemia in mice. Stroke 44, 190-197. doi: 10.1161/strokeaha.112.670299
24. Hubert, S., Rissiek, B., Klages, K., Huehn, J., Sparwasser, T., Haag, F., et al. (2010). Extracellular NAD+ shapes the Foxp3+ regulatory T cell compartment through the ART2-P2X7 pathway. J. Exp. Med. 207, 2561-2568. doi: 10.1084/jem.20091154
25. Iadecola, C., and Anrather, J. (2011). The immunology of stroke: from mechanisms to translation. Nat. Med. 17, 796-808. doi: 10.1038/nm.2399
26. Jähnichen, S., Blanchetot, C., Maussang, D., Gonzalez-Pajuelo, M., Chow, K. Y., Bosch, L., et al. (2010). CXCR4 nanobodies (VHH-based single variable domains) potently inhibit chemotaxis and HIV-1 replication and mobilize stem cells. Proc. Natl. Acad. Sci. U S A 107, 20565-20570. doi: 10.1073/pnas.1012865107
27. Koch-Nolte, F., Reyelt, J., Schössow, B., Schwarz, N., Scheuplein, F., Rothenburg, S., et al. (2007). Single domain antibodies from llama effectively and specifically block T cell ecto-ADP-ribosyltransferase ART2.2 in vivo. FASEB J. 21, 3490-3498. doi: 10.1096/fj.07-8661com
28. Komine-Kobayashi, M., Chou, N., Mochizuki, H., Nakao, A., Mizuno, Y., and Urabe, T. (2004). Dual role of Fcgamma receptor in transient focal cerebral ischemia in mice. Stroke 35, 958-963. doi: 10.1161/01.str.0000120321.30916.8e
29. Kopf, M., Bachmann, M. F., and Marsland, B. J. (2010). Averting inflammation by targeting the cytokine environment. Nat. Rev. Drug Discov. 9, 703-718. doi: 10.1038/nrd2805
30. Laeremans, T., Stortelers, C., Koch-Nolte, F., Gonzalez, M., Assuncao, J., and van Rompaey, P. (2010). Genetic immunization for producing immunoglobulins against cell-associated antigens such as p2x7, cxcr7 or cxcr4. Patent
31. Li, T., Bourgeois, J. P., Celli, S., Glacial, F., Le Sourd, A. M., Mecheri, S., et al. (2012). Cell-penetrating anti-GFAP VHH and corresponding fluorescent fusion protein VHH-GFP spontaneously cross the blood-brain barrier and specifically recognize astrocytes: application to brain imaging. FASEB J. 26, 3969-3979. doi: 10.1096/fj.11-201384
32. Magnus, T., Wiendl, H., and Kleinschnitz, C. (2012). Immune mechanisms of stroke. Curr. Opin. Neurol. 25, 334-340. doi: 10.1097/WCO.0b013e328352ede6
33. Maussang, D., Mujić-Delić, A., Descamps, F. J., Stortelers, C., Vanlandschoot, P., Stigter-van Walsum, M., et al. (2013). Llama-derived single variable domains (nanobodies) directed against chemokine receptor CXCR7 reduce head and neck cancer cell growth in vivo. J. Biol. Chem. 288, 29562-29572. doi: 10.1074/jbc.m113.498436
34. Menzel, S., Rissiek, B., Haag, F., Goldbaum, F. A., and Koch-Nolte, F. (2013). The art of blocking ADP-ribosyltransferases (ARTs): nanobodies as experimental and therapeutic tools to block mammalian and toxin ARTs.FEBS J. 280, 3543-3550. doi: 10.1111/febs.12313
35. Muhammad, S., Barakat, W., Stoyanov, S., Murikinati, S., Yang, H., Tracey, K. J., et al. (2008). The HMGB1 receptor RAGE mediates ischemic brain damage. J. Neurosci. 28, 12023-12031. doi: 10.1523/JNEUROSCI.2435-08.2008
36. Muruganandam, A., Tanha, J., Narang, S., and Stanimirovic, D. (2002). Selection of phage-displayed llama single-domain antibodies that transmigrate across human blood-brain barrier endothelium. FASEB J. 16, 240-242. doi: 10.1096/fj.01-0343fje
37. Muyldermans, S. (2013). Nanobodies: natural single-domain antibodies. Annu. Rev. Biochem. 82, 775-797. doi: 10.1146/annurev-biochem-063011-092449
38. Nimmerjahn, F., and Ravetch, J. V. (2007). Fc-receptors as regulators of immunity. Adv. Immunol. 96, 179-204. doi: 10.1016/s0065-2776(07)96005-8
39. Pardridge, W. M. (2012). Drug transport across the blood-brain barrier. J. Cereb. Blood Flow Metab. 32, 1959-1972. doi: 10.1038/jcbfm.2012.126
40. Rissiek, B., Danquah, W., Haag, F., and Koch-Nolte, F. (2014a). Technical Advance: a new cell preparation strategy that greatly improves the yield of vital and functional Tregs and NKT cells. J. Leukoc. Biol. 95, 543-549. doi: 10.1189/jlb.0713407
41. Rissiek, B., Haag, F., Boyer, O., Koch-Nolte, F., and Adriouch, S. (2014b). ADP-Ribosylation of P2X7: a matter of life and death for regulatory T cells and natural killer T cells. Curr. Top. Microbiol. Immunol. doi: 10.1007/82_2014_420. [Epub ahead of print].
42. Rozan, C., Cornillon, A., Pétiard, C., Chartier, M., Behar, G., Boix, C., et al. (2013). Single-domain antibody-based and linker-free bispecific antibodies targeting Fc γ RIII induce potent antitumor activity without recruiting regulatory T cells. Mol. Cancer Ther. 12, 1481-1491. doi: 10.1158/1535-7163.mct-12-1012
43. Ruscher, K., Kuric, E., Liu, Y., Walter, H. L., Issazadeh-Navikas, S., Englund, E., et al. (2013). Inhibition of CXCL12 signaling attenuates the postischemic immune response and improves functional recovery after stroke. J. Cereb. Blood Flow Metab. 33, 1225-1234. doi: 10.1038/jcbfm.2013.71
44. Scheuplein, F., Rissiek, B., Driver, J. P., Chen, Y.-G., Koch-Nolte, F., and Serreze, D. V. (2010). A recombinant heavy chain antibody approach blocks ART2 mediated deletion of an iNKT cell population that upon activation inhibits autoimmune diabetes. J. Autoimmun. 34, 145-154. doi: 10.1016/j.jaut.2009.08.012
45. Seman, M., Adriouch, S., Scheuplein, F., Krebs, C., Freese, D., Glowacki, G., et al. (2003). NAD-induced T cell death: ADP-ribosylation of cell surface proteins by ART2 activates the cytolytic P2X7 purinoceptor. Immunity 19, 571-582. doi: 10.1016/S1074-7613(03)00266-8
46. Sousa, L. F. D. C., Coelho, F. M., Rodrigues, D. H., Campos, A. C., Barcelos, L. D. S., Teixeira, M. M., et al. (2013). Blockade of CXCR1/2 chemokine receptors protects against brain damage in ischemic stroke in mice. Clinics (Sao Paulo) 68, 391-394. doi: 10.6061/clinics/2013(03)oa17
47. Sundberg, E. J., and Mariuzza, R. A. (2002). Molecular recognition in antibody-antigen complexes. Adv. Protein Chem. 61, 119-160. doi: 10.1016/s0065-3233(02)61004-6
48. Tijink, B. M., Laeremans, T., Budde, M., Stigter-van Walsum, M., Dreier, T., de Haard, H. J., et al. (2008). Improved tumor targeting of anti-epidermal growth factor receptor Nanobodies through albumin binding: taking advantage of modular Nanobody technology. Mol. Cancer Ther. 7, 2288-2297. doi: 10.1158/1535-7163.mct-07-2384
49. Tsai, L.-K., Wang, Z., Munasinghe, J., Leng, Y., Leeds, P., and Chuang, D.-M. (2011). Mesenchymal stem cells primed with valproate and lithium robustly migrate to infarcted regions and facilitate recovery in a stroke model. Stroke 42, 2932-2939. doi: 10.1161/strokeaha.110.612788
50. Van Bockstaele, F., Holz, J. B., and Revets, H. (2009). The development of nanobodies for therapeutic applications. Curr. Opin. Investig. Drugs 10, 1212-1224.
51. Vandenbroucke, K., de Haard, H., Beirnaert, E., Dreier, T., Lauwereys, M., Huyck, L., et al. (2010). Orally administered L. lactis secreting an anti-TNF Nanobody demonstrate efficacy in chronic colitis. Mucosal Immunol. 3, 49-56. doi: 10.1038/mi.2009.116
52. Wang, D., El-Amouri, S. S., Dai, M., Kuan, C.-Y., Hui, D. Y., Brady, R. O., et al. (2013). Engineering a lysosomal enzyme with a derivative of receptor-binding domain of apoE enables delivery across the blood-brain barrier. Proc. Natl. Acad. Sci. U S A 110, 2999-3004. doi: 10.1073/pnas.1222742110
53. Wesolowski, J., Alzogaray, V., Reyelt, J., Unger, M., Juarez, K., Urrutia, M., et al. (2009). Single domain antibodies: promising experimental and therapeutic tools in infection and immunity. Med. Microbiol. Immunol. 198, 157-174. doi: 10.1007/s00430-009-0116-7
54. Williams, S. C. P. (2013). Small nanobody drugs win big backing from pharma. Nat. Med. 19, 1355-1356. doi: 10.1038/nm1113-1355
55. Xiao, G., and Gan, L.-S. (2013). Receptor-mediated endocytosis and brain delivery of therapeutic biologics. Int. J. Cell Biol. 2013:703545. doi: 10.1155/2013/703545